Nurix Therapeutics, Inc.
NRIX scores 33.7 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-0.4 points) applied. NRIX's rank of #1020 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| NRIX | 33.7 | N/A | 54.0% | -314.9% | $1.4B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 85.6 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 82.1 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $121.8B |
| ASND | 75.8 | 16.6 | 98.0% | -31.7% | $13.8B |
| NBIX | 74.8 | 26.5 | 21.4% | 16.7% | $13.1B |
| AMGN | 73.9 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.5 | 35.1 | 78.6% | 38.0% | $47.4B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.4 | 19.4 | 1.0% | 31.4% | $80.2B |
| ISRG | 72.2 | 61.7 | 20.5% | 28.4% | $180.9B |
| EXEL | 71.6 | 15.1 | 7.0% | 33.7% | $11.9B |
| ALKS | 71.5 | 16.5 | -6.4% | 23.9% | $5.0B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $7.9B |
| HALO | 70.3 | 16.8 | 22.4% | 43.7% | $8.2B |
| Sector Average | 37.0 | 41.9 | 161.5% | -3292.7% | โ |
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $14M | $8M | $44M | $18M |
| Gross Profit | $9M | $3M | $-34M | $-51M |
| Operating Income | $-83M | $-91M | $-48M | $-63M |
| Net Income | $-78M | $-86M | $-43M | $-56M |
| EPS (Diluted) | $-0.82 | $-1.03 | $-0.52 | $-0.67 |
| Gross Margin | 65.9% | 36.7% | -77.3% | -277.5% |
| Operating Margin | -612.0% | -1157.7% | -109.7% | -340.7% |
| Net Margin | -576.1% | -1094.8% | -98.7% | -305.4% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $21.53 | $47.84 | 75.9% | Wide |
| 2022 | $7.52 | $30.52 | 120.9% | Wide |
| 2023 | $4.22 | $13.99 | 107.3% | Wide |
| 2024 | $7.65 | $29.56 | 117.8% | Wide |
| 2025 | $8.18 | $22.50 | 93.4% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.